We invest in biotech and medtech innovation across the full lifecycle from company creation to venture capital, alternative financing, and public companies.
AUM: $14.1B · Form ADV, 30 Mar 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: PTGX | Current | Pharmaceutical Preparations | COM | 5,061,175 | 0 | 0.0% | 7.75% | $713M | +$93M | 7.19% | $8.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ARGX | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADR | 711,584 | +2,138 | +0.3% | $682M | +$24M | 6.88% | $59.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CGON | Current | Biological Products, (No Diagnostic Substances) | COM | 8,514,590 | 0 | 0.0% | 9.53% | $604M | -$1M | 6.08% | $7.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRTC | Current | Surgical & Medical Instruments & Apparatus | COM | 3,118,913 | +936,282 | +42.9% | 9.28% | $354M | +$95M | 3.57% | $3.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: INSM | Current | Pharmaceutical Preparations | COM PAR $.01 | 3,096,545 | -1,746,335 | -36.1% | 1.41% | $353M | -$163M | 3.56% | $31.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TNGX | Current | Pharmaceutical Preparations | COM | 14,048,477 | +147,857 | +1.1% | 8.29% | $351M | -$84M | 3.53% | $3.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ERAS | Current | Pharmaceutical Preparations | COM | 22,446,754 | +4,500,000 | +25.1% | 6.40% | $329M | +$0.3M | 3.32% | $5.0B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Current | Pharmaceutical Preparations | COM NEW | 3,691,791 | -560,205 | -13.2% | 3.89% | $329M | -$49M | 3.31% | $9.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: RDNT | Current | Services-Medical Laboratories | COM | 4,630,697 | -216,261 | -4.5% | 5.88% | $319M | +$20M | 3.22% | $5.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TARS | Current | Biological Products, (No Diagnostic Substances) | COM | 3,484,066 | +127,007 | +3.8% | 7.07% | $274M | +$63M | 2.76% | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ZLAB | Current | Pharmaceutical Preparations | ADR | 10,350,973 | +3,776,941 | +57.5% | $273M | +$148M | 2.75% | $2.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: RGEN | Current | Biological Products, (No Diagnostic Substances) | COM | 1,385,398 | +144,761 | +11.7% | 2.17% | $266M | +$97M | 2.68% | $10.9B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GH | Current | Services-Medical Laboratories | COM | 1,481,033 | 0 | 0.0% | 1.09% | $264M | +$42M | 2.66% | $19.7B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CELC | Current | Services-Medical Laboratories | COM | 3,304,903 | 0 | 0.0% | 6.73% | $263M | -$83M | 2.65% | $2.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORKA | Current | Pharmaceutical Preparations | COM | 3,139,030 | 0 | 0.0% | 4.63% | $261M | -$37M | 2.64% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: NTRA | Current | Services-Medical Laboratories | COM | 600,000 | -400,000 | -40.0% | 0.41% | $248M | -$23M | 2.50% | $42.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CYTK | Current | Pharmaceutical Preparations | COM NEW | 2,862,003 | 0 | 0.0% | 2.05% | $189M | -$55M | 1.90% | $7.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: URGN | Current | Pharmaceutical Preparations | COM | 4,543,895 | 0 | 0.0% | 9.26% | $185M | +$17M | 1.86% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Establishment Labs Hldgs Inc | Current | COM | 2,665,695 | +10,000 | +0.4% | $171M | -$57M | 1.72% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: XNCR | Current | Pharmaceutical Preparations | COM | 6,827,461 | +50,000 | +0.7% | 9.10% | $170M | +$61M | 1.72% | $2.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MDGL | Current | Pharmaceutical Preparations | COM | 312,817 | -1,680,870 | -84.3% | 1.35% | $158M | -$913M | 1.59% | $9.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Immunocore Holdings plc | Nasdaq: IMCR | Current | Biological Products, (No Diagnostic Substances) | ADS | 4,869,798 | 0 | 0.0% | 9.42% | $148M | -$7M | 1.49% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | COM | 5,623,525 | 0 | 0.0% | 8.60% | $146M | -$38M | 1.47% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ACAD | Current | Pharmaceutical Preparations | COM | 7,144,524 | 0 | 0.0% | 4.13% | $144M | -$37M | 1.45% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: KOD | Current | Biological Products, (No Diagnostic Substances) | COM | 1,487,934 | 0 | 0.0% | 2.28% | $141M | +$83M | 1.42% | $6.4B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| GH Research PLC | Nasdaq: GHRS | Current | Pharmaceutical Preparations | ORDINARY SHARES | 5,933,815 | 0 | 0.0% | $139M | -$20M | 1.40% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CMPS | Current | Pharmaceutical Preparations | SPONSORED ADS | 10,948,591 | +247,617 | +2.3% | 7.73% | $136M | -$15M | 1.37% | $1.2B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: NBIX | Current | Biological Products, (No Diagnostic Substances) | COM | 942,684 | -325,241 | -25.7% | 0.93% | $134M | -$80M | 1.35% | $15.8B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RARE | Current | Pharmaceutical Preparations | COM | 8,529,394 | +732,499 | +9.4% | 8.37% | $128M | -$132M | 1.29% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Kailera Therapeutics, Inc. | Nasdaq: KLRA | Current | Pharmaceutical Preparations | COMMON STOCK | 10,776,820 | 0 | 0.0% | 8.30% | $123M | -$114M | 1.24% | $1.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BLTE | Current | Pharmaceutical Preparations | SPONSORED ADS | 715,332 | 0 | 0.0% | $121M | +$11M | 1.22% | $6.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: IMTX | Current | Biological Products, (No Diagnostic Substances) | SHS | 13,521,551 | +575,375 | +4.4% | $119M | -$12M | 1.20% | $906M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: REPL | Current | Biological Products, (No Diagnostic Substances) | COM | 8,491,525 | +1,079,944 | +14.6% | 8.96% | $112M | +$30M | 1.13% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMVT | Current | Biological Products, (No Diagnostic Substances) | COM | 3,177,849 | 0 | 0.0% | 1.54% | $107M | -$15M | 1.08% | $6.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PTCT | Current | Pharmaceutical Preparations | COM | 1,615,819 | -6,130,596 | -79.1% | 1.93% | $105M | -$527M | 1.06% | $4.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Viridian Therapeutics, Inc.\DE | Nasdaq: VRDN | Current | Pharmaceutical Preparations | COM | 4,910,126 | +4,910,126 | New | 4.32% | $101M | +$101M | 1.02% | $3.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CSTL | Current | Services-Medical Laboratories | COM | 2,778,335 | 0 | 0.0% | 9.02% | $99M | +$32M | 0.99% | $1.0B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Uniqure NV | Current | SHS | 3,941,572 | 0 | 0.0% | $95M | -$86M | 0.96% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: COGT | Current | Pharmaceutical Preparations | COM | 2,309,021 | 0 | 0.0% | 1.33% | $74M | -$15M | 0.75% | $4.8B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GPCR | Current | Pharmaceutical Preparations | SPONSORED ADS | 2,282,138 | +674,631 | +42.0% | 1.06% | $71M | -$15M | 0.72% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AXGN | Current | Electromedical & Electrotherapeutic Apparatus | COM | 1,659,376 | +647,800 | +64.0% | 2.78% | $70M | +$23M | 0.70% | $3.4B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TSHA | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 13,560,258 | 0 | 0.0% | 4.16% | $66M | -$26M | 0.67% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Orchestra BioMed Holdings, Inc. | Nasdaq: OBIO | Current | Surgical & Medical Instruments & Apparatus | COM | 9,556,063 | 0 | 0.0% | 12.14% | $59M | +$18M | 0.60% | $551M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: VSTM | Current | Pharmaceutical Preparations | COM NEW | 6,718,081 | +82,288 | +1.2% | 5.33% | $54M | +$29M | 0.55% | $864M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: DHR | Current | Industrial Instruments For Measurement, Display, and Control | COM | 230,000 | 0 | 0.0% | 0.03% | $51M | +$7M | 0.51% | $155B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: HNGE | Current | Services-Computer Processing & Data Preparation | CL A | 500,000 | 0 | 0.0% | $49M | +$7M | 0.49% | $8.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: RCKT | Current | Pharmaceutical Preparations | COM | 17,687,772 | -350,000 | -1.9% | 15.84% | $47M | -$14M | 0.47% | $236M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SLDB | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 5,905,426 | +2,012,500 | +51.7% | 5.29% | $43M | +$4M | 0.43% | $719M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Neurogene Inc. | Nasdaq: NGNE | Current | Pharmaceutical Preparations | COM | 1,512,456 | +150,000 | +11.0% | 7.31% | $42M | -$0.8M | 0.42% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CGEM | Current | Biological Products, (No Diagnostic Substances) | COM | 2,364,347 | 0 | 0.0% | 3.64% | $36M | -$7M | 0.37% | $589M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AQST | Current | Pharmaceutical Preparations | COM | 7,426,471 | 0 | 0.0% | 5.91% | $34M | +$3M | 0.35% | $466M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CADL | Current | Biological Products, (No Diagnostic Substances) | COM | 3,211,008 | -3,211,010 | -50.0% | 4.09% | $34M | -$33M | 0.34% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: AKTS | Current | Pharmaceutical Preparations | COM | 1,592,043 | 0 | 0.0% | $31M | -$20M | 0.31% | $915M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: SVRA | Current | Pharmaceutical Preparations | COM | 5,952,380 | 0 | 0.0% | 2.70% | $31M | -$6M | 0.31% | $1.1B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Korsana Biosciences, Inc. | Nasdaq: KRSA | Current | Pharmaceutical Preparations | COM | 877,020 | +877,020 | New | 1.93% | $28M | +$28M | 0.28% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: KYMR | Current | Biological Products, (No Diagnostic Substances) | COM | 240,000 | 0 | 0.0% | 0.28% | $27M | -$0.7M | 0.27% | $10.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Dianthus Therapeutics, Inc. /DE/ | Nasdaq: DNTH | Current | Pharmaceutical Preparations | COM | 248,063 | 0 | 0.0% | 0.44% | $22M | -$2M | 0.22% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BBNX | Current | Surgical & Medical Instruments & Apparatus | COM | 998,855 | -501,145 | -33.4% | 1.84% | $19M | -$5M | 0.19% | $724M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LRMR | Current | Pharmaceutical Preparations | COM | 5,820,891 | +3,254,892 | +126.8% | 5.56% | $19M | +$11M | 0.19% | $337M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Pyxis Oncology, Inc. | Nasdaq: PYXS | Current | Pharmaceutical Preparations | COMMON STOCK | 6,506,229 | +6,506,229 | New | 5.44% | $15M | +$15M | 0.15% | $201M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: IPSC | Current | Biological Products, (No Diagnostic Substances) | COM | 8,695,652 | 0 | 0.0% | 4.79% | $15M | -$6M | 0.15% | $240M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BEAM | Current | Biological Products, (No Diagnostic Substances) | COM | 570,394 | 0 | 0.0% | 0.55% | $14M | -$6M | 0.14% | $2.2B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Surrozen, Inc./DE | Nasdaq: SRZN | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 393,560 | +393,560 | New | 2.06% | $13M | +$13M | 0.13% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: HTFL | Current | Surgical & Medical Instruments & Apparatus | COM | 250,000 | -45,000 | -15.3% | 0.28% | $12M | +$4M | 0.13% | $3.9B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FRNM | Current | Services-Medical Laboratories | COMMON STOCK | 742,500 | +742,500 | New | 0.67% | $12M | +$12M | 0.12% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Latigo Biotherapeutics, Inc. | Nasdaq: LTGO | Current | Pharmaceutical Preparations | COM | 700,000 | +700,000 | New | 1.06% | $12M | +$12M | 0.12% | $878M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Silence Therapeutics plc | Nasdaq: SLN | Current | Pharmaceutical Preparations | ADS | 700,000 | +700,000 | New | 0.38% | $8M | +$8M | 0.08% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: OCGN | Current | Biological Products, (No Diagnostic Substances) | COM | 6,666,666 | 0 | 0.0% | 1.96% | $7M | -$3M | 0.07% | $249M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Milestone Pharmaceuticals Inc. | Nasdaq: MIST | Current | Pharmaceutical Preparations | COM | 7,833,336 | 0 | 0.0% | 6.29% | $7M | -$4M | 0.07% | $50M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ADRX | Current | Pharmaceutical Preparations | COM | 300,000 | +300,000 | New | 0.27% | $6M | +$6M | 0.06% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CBIO | Current | Pharmaceutical Preparations | COM | 372,856 | 0 | 0.0% | 0.96% | $5M | -$1M | 0.05% | $539M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Allogene Therapeutics, Inc. | Nasdaq: ALLO | Current | Biological Products, (No Diagnostic Substances) | COM | 3,250,000 | 0 | 0.0% | 0.94% | $5M | -$2M | 0.05% | $231M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Lumexa Imaging Holdings, Inc. | Nasdaq: LMRI | Current | Services-Medical Laboratories | COM | 500,000 | -150,000 | -23.1% | 0.52% | $5M | -$2M | 0.05% | $1.4B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DYN | Current | Pharmaceutical Preparations | COM | 300,000 | +300,000 | New | 0.16% | $5M | +$5M | 0.05% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| REGENXBIO Inc. | Nasdaq: RGNX | Current | Biological Products, (No Diagnostic Substances) | COM | 555,555 | +555,555 | New | 0.84% | $4M | +$4M | 0.04% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Kalaris Therapeutics, Inc. | Nasdaq: KLRS | Current | Biological Products, (No Diagnostic Substances) | COM | 1,300,000 | 0 | 0.0% | 5.46% | $4M | -$2M | 0.04% | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ABVX | Current | Pharmaceutical Preparations | SPONSORED ADS | 26,400 | 0 | 0.0% | $3M | -$0.9M | 0.03% | $7.1B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Medline Inc. | Nasdaq: MDLN | Current | Surgical & Medical Instruments & Apparatus | COM CL A | 70,000 | 0 | 0.0% | $2M | -$0.3M | 0.02% | $49.8B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | COM NEW | 250,000 | 0 | 0.0% | 0.43% | $2M | -$4M | 0.02% | $438M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRON | Current | Pharmaceutical Preparations | COM | 30,000 | 0 | 0.0% | 0.07% | $2M | -$0.2M | 0.02% | $3.5B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Evommune, Inc. | NYSE: EVMN | Current | Pharmaceutical Preparations | COM SHS | 208,071 | -1,294,164 | -86.1% | 0.50% | $2M | -$18M | 0.02% | $299M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Obsidian Therapeutics, Inc. | Nasdaq: OBX | Current | Pharmaceutical Preparations | COM | 67,706 | +67,706 | New | 0.11% | $0.9M | +$0.9M | 0.01% | $751M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Lexeo Therapeutics, Inc. | Nasdaq: LXEO | Current | Biological Products, (No Diagnostic Substances) | COM | 239,149 | +239,149 | New | 0.29% | $0.8M | +$0.8M | 0.01% | $244M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Avidity Biosciences Inc | Exited | COM | 0 | -11,372,829 | -100.0% | -$496M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Verona Pharma PLC | Exited | SPONSORED ADS | 0 | -3,051,878 | -100.0% | -$289M | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| NYSE: PEN | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -866,499 | -100.0% | -$269M | $12.6B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Akero Therapeutics Inc | Exited | COM | 0 | -5,477,561 | -100.0% | -$260M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Apogee Therapeutics Inc | Exited | COM | 0 | -2,782,097 | -100.0% | -$234M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Nasdaq: GERN | Exited | Pharmaceutical Preparations | COM | 0 | -44,111,916 | -100.0% | -$200M | $588M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Merus N V | Exited | COM | 0 | -2,025,277 | -100.0% | -$191M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: AXSM | Exited | Pharmaceutical Preparations | COM | 0 | -888,001 | -100.0% | -$162M | $7.1B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Apellis Pharmaceuticals Inc | Exited | COM | 0 | -3,685,045 | -100.0% | -$148M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| Exited | COM | 0 | -2,481,119 | -100.0% | -$145M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||||||
| Nasdaq: ISRG | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM NEW | 0 | -220,000 | -100.0% | -$101M | $138B | Q2 2026 | 14 Aug 2026 | Q1 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: PODD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -324,600 | -100.0% | -$92M | $9.5B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Masimo Corp | Exited | COM | 0 | -683,294 | -100.0% | -$89M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: ALKS | Exited | Pharmaceutical Preparations | SHS | 0 | -1,672,356 | -100.0% | -$88M | $7.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: GMED | Exited | Surgical & Medical Instruments & Apparatus | CL A | 0 | -1,125,000 | -100.0% | -$82M | $9.1B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Centessa Pharmaceuticals PLC | Exited | SPONSORED ADS | 0 | -2,054,175 | -100.0% | -$82M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: ABT | Exited | Pharmaceutical Preparations | COM | 0 | -444,000 | -100.0% | -$60M | $180B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| RAPT Therapeutics | Exited | COM NEW | 0 | -1,637,165 | -100.0% | -$55M | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Crinetics Pharmaceuticals Inc | Exited | COM | 0 | -1,451,326 | -100.0% | -$53M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||||
| NYSE: DGX | Exited | Services-Medical Laboratories | COM | 0 | -250,000 | -100.0% | -$48M | $28.5B | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: LENZ | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -863,389 | -100.0% | -$40M | $105M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: WAY | Exited | Services-Computer Integrated Systems Design | COM | 0 | -1,630,000 | -100.0% | -$39M | $5.2B | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: ARWR | Exited | Pharmaceutical Preparations | COM | 0 | -585,682 | -100.0% | -$37M | $6.2B | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Soleno Therapeutics Inc | Exited | COM | 0 | -424,408 | -100.0% | -$36M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: MLTX | Exited | Pharmaceutical Preparations | CLASS A ORD | 0 | -741,090 | -100.0% | -$35M | $939M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: SYK | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -100,000 | -100.0% | -$33M | $118B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: GEHC | Exited | X-Ray Apparatus & Tubes & Related Irradiation Apparatus | COMMON STOCK | 0 | -393,500 | -100.0% | -$30M | $37.0B | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: ARVN | Exited | Pharmaceutical Preparations | COM | 0 | -3,334,308 | -100.0% | -$23M | $441M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: CMPX | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -4,186,599 | -100.0% | -$22M | $122M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: ALEC | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -6,990,806 | -100.0% | -$21M | $342M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Fulgent Genetics, Inc. | Nasdaq: FLGT | Exited | Services-Medical Laboratories | COM | 0 | -1,289,000 | -100.0% | -$20M | $692M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | |||
| 89bio Inc | Exited | COM | 0 | -1,967,527 | -100.0% | -$19M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: DFTX | Exited | Medicinal Chemicals & Botanical Products | COM SHS | 0 | -400,000 | -100.0% | -$19M | $4.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| NYSE: GKOS | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -190,000 | -100.0% | -$19M | $14.1B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: ROIV | Exited | Pharmaceutical Preparations | SHS | 0 | -1,454,273 | -100.0% | -$17M | $28.2B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Sage Therapeutics Inc | Exited | COM | 0 | -3,002,370 | -100.0% | -$16M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Tourmaline Bio Inc | Exited | COM | 0 | -736,681 | -100.0% | -$15M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: IDYA | Exited | Pharmaceutical Preparations | COM | 0 | -370,370 | -100.0% | -$14M | $2.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Tempus AI, Inc. | Nasdaq: TEM | Exited | Services-Computer Programming, Data Processing, Etc. | CL A | 0 | -200,000 | -100.0% | -$12M | $10.9B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||
| 10x Genomics, Inc. | Nasdaq: TXG | Exited | Laboratory Analytical Instruments | CL A COM | 0 | -502,856 | -100.0% | -$11M | $7.5B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: CTMX | Exited | Pharmaceutical Preparations | COM | 0 | -3,461,500 | -100.0% | -$11M | $447M | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Ataibeckley Inc | Exited | COM SHS | 0 | -2,000,000 | -100.0% | -$11M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||||
| NYSE: IQV | Exited | Services-Commercial Physical & Biological Research | COM | 0 | -46,000 | -100.0% | -$10M | $41.3B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| TENAX THERAPEUTICS, INC. | Nasdaq: TENX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -696,570 | -100.0% | -$10M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Atai Beckley NV | Exited | SHS | 0 | -2,000,000 | -100.0% | -$8M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Perceptive Cap Solutions Cor | Exited | CL A ORD SHS | 0 | -742,500 | -100.0% | -$8M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Nasdaq: JBIO | Exited | Pharmaceutical Preparations | COM NEW | 0 | -573,205 | -100.0% | -$8M | $1.0B | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: WVE | Exited | Pharmaceutical Preparations | SHS | 0 | -1,350,000 | -100.0% | -$8M | $536M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Allurion Technologies Inc | ALURW | Exited | COMMON STOCK | 0 | -5,891,430 | -100.0% | -$7M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | |||||
| Inventiva S.A. | Nasdaq: IVA | Exited | Pharmaceutical Preparations | ADS | 0 | -1,298,702 | -100.0% | -$7M | $825M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: PEPG | Exited | Pharmaceutical Preparations | COM | 0 | -1,500,000 | -100.0% | -$7M | $370M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: FDMT | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -475,737 | -100.0% | -$6M | $604M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: MAZE | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -212,000 | -100.0% | -$6M | $1.8B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Cargo Therapeutics Inc | Exited | COM | 0 | -1,212,562 | -100.0% | -$5M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Mind Medicine Mindmed Inc | Exited | COM NEW | 0 | -300,000 | -100.0% | -$4M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: CRVS | Exited | Pharmaceutical Preparations | COM | 0 | -447,607 | -100.0% | -$3M | $844M | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| Kestra Medical Technologies Ltd. | Exited | SHS | 0 | -200,000 | -100.0% | -$3M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: AVTX | Exited | Pharmaceutical Preparations | COM NEW | 0 | -175,000 | -100.0% | -$3M | $390M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Acelyrin Inc | Exited | COM | 0 | -978,310 | -100.0% | -$3M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: BIOA | Exited | Pharmaceutical Preparations | COM | 0 | -786,353 | -100.0% | -$3M | $216M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: CBLL | Exited | Electromedical & Electrotherapeutic Apparatus | COM | 0 | -150,000 | -100.0% | -$3M | $1.0B | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: OMDA | Exited | Services-Health Services | COM | 0 | -200,000 | -100.0% | -$3M | $775M | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Essa Pharma Inc | Exited | COM NEW | 0 | -1,113,002 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| ImageneBio, Inc. | Nasdaq: IMA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -334,445 | -100.0% | -$2M | $50M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q2 2026 | 13F, Q2 2026 | |||
| SAB Biotherapeutics, Inc. | Nasdaq: SABS | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -635,276 | -100.0% | -$2M | $262M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: ARTV | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -148,844 | -100.0% | -$2M | $189M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: XGN | Exited | Services-Medical Laboratories | COM | 0 | -195,000 | -100.0% | -$0.9M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||||
| Adagio Med Hldgs Inc | Exited | COM | 0 | -209,361 | -100.0% | -$0.4M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| IMMUNIC, INC. | Nasdaq: IMUX | Exited | Pharmaceutical Preparations | COM | 0 | -402,107 | -100.0% | -$0.3M | $117M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 |